Exposure to PFAS—a class of synthetic chemicals utilized in food wrappers, nonstick cookware and other products—reprograms the metabolism of benign and malignant human prostate cells to a more energy efficient state that ...
Nov 11, 2021
0
45
Since 1971, when the U.S. government made defeating cancer a goal and put major funding behind it, death rates for many cancers have plummeted, but some are increasing, according to a new American Cancer Society report.
Nov 11, 2021
0
11
Regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with docetaxel, according to research presented at the NCRI Festival.
Nov 10, 2021
0
1
Black, Hispanic, and Asian men whose results on a common prostate cancer screening test indicated a need for additional testing were less likely than their white counterparts to receive an increasingly used follow-up test ...
Nov 08, 2021
0
86
Many patients with prostate cancer are treated with drugs that lower or block hormones that fuel tumor growth. While the drugs are effective for a time, most patients eventually develop resistance to these therapies.
Nov 05, 2021
0
17
A trio of drugs could delay the progression of metastatic castration-resistant prostate cancer.
Nov 03, 2021
0
12
Researchers at the University of East Anglia have shown that a prostate cancer urine test can identify men at 'intermediate risk' who can safely avoid immediate treatment and benefit from 'active surveillance' instead.
Nov 03, 2021
0
5
The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center. The studies ...
Nov 02, 2021
0
2
Cleveland Clinic researchers have shown for the first time that diet-associated molecules in the gut are associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. Findings from the ...
Oct 28, 2021
0
4
A primary endpoint analysis of the NRG Oncology Phase III clinical trial NRG-GU003 comparing hypofractionated post-operative prostate bed radiotherapy (HYPORT) to the conventional post-prostatectomy radiotherapy (COPORT) ...
Oct 26, 2021
0
2
